Literature DB >> 24049633

BMD change predicts bone fracture risk due to zoledronate treatment.

.   

Abstract

Entities:  

Year:  2012        PMID： 24049633      PMCID： PMC3727811          DOI： 10.1038/bonekey.2012.205

Source DB:  PubMed          Journal:  Bonekey Rep        ISSN： 2047-6396


× No keyword cloud information.
  3 in total

1.  Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT).

Authors:  Richard M Jacques; Steven Boonen; Felicia Cosman; Ian R Reid; Douglas C Bauer; Dennis M Black; Richard Eastell
Journal:  J Bone Miner Res       Date:  2012-08       Impact factor: 6.741

2.  Bone strength and surrogate markers: the first, second, and third fiddle.

Authors:  Paul D Miller
Journal:  J Bone Miner Res       Date:  2012-08       Impact factor: 6.741

3.  Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.

Authors:  Matthew Austin; Yu-Ching Yang; Eric Vittinghoff; Silvano Adami; Steven Boonen; Douglas C Bauer; Gerolamo Bianchi; Michael A Bolognese; Claus Christiansen; Richard Eastell; Andreas Grauer; Federico Hawkins; David L Kendler; Beatriz Oliveri; Michael R McClung; Ian R Reid; Ethel S Siris; Jose Zanchetta; Cristiano A F Zerbini; Cesar Libanati; Steven R Cummings
Journal:  J Bone Miner Res       Date:  2012-03       Impact factor: 6.741
  3 in total
  1 in total

Review 1.  Bone health and HIV in resource-limited settings: a scoping review.

Authors:  Flavia Kiweewa Matovu; Lalita Wattanachanya; Mags Beksinska; John M Pettifor; Kiat Ruxrungtham
Journal:  Curr Opin HIV AIDS       Date:  2016-05       Impact factor: 4.283
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.